XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Statement Details (Tables)
6 Months Ended
Jun. 30, 2018
Disclosure of Financial Statement Details [Abstract]  
Financial Statement Details
Financial Statement Details (in millions)
Short-Term Marketable Securities
Short-term marketable securities, consisting of equity and debt securities, were as follows:
 
June 30, 2018
 
Cost or Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
 
 
 
 
 
 
 
 
Equity investment in Tandem Diabetes Care, Inc
$
5.0

 
$
50.1

 
$

 
$
55.1

 
 
 
 
 
 
 
 
Debt securities, available for sale
 
 
 
 
 
 
 
U.S. government agencies
$
199.6

 
$

 
$
(0.2
)
 
$
199.4

Commercial paper
49.3

 

 

 
49.3

Corporate debt
2.1

 

 

 
2.1

Total available-for-sale debt securities
$
251.0

 
$

 
$
(0.2
)
 
$
250.8

 
 
 
 
 
 
 
 
Total marketable securities
$
256.0

 
$
50.1

 
$
(0.2
)
 
$
305.9

Gross unrealized gain on our equity investment in Tandem Diabetes Care, Inc. of $42.7 million and $50.1 million for three and six months ended June 30, 2018, respectively is included in our Consolidated Statements of Operations under "Income from equity investments."
 
December 31, 2017
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
U.S. government agencies
$
87.5

 
$

 
$
(0.2
)
 
$
87.3

Corporate debt
14.7

 

 

 
14.7

Commercial paper
5.1

 

 

 
5.1

Total marketable securities
$
107.3

 
$

 
$
(0.2
)
 
$
107.1


As of June 30, 2018, the estimated market value of available-for-sale marketable securities with contractual maturities of up to one year and up to 13 months were $249.8 million and $1.0 million, respectively. We do not generally intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.
Inventory
 
June 30, 2018
 
December 31, 2017
Raw materials
$
21.7

 
$
20.0

Work-in-process
9.7

 
8.2

Finished goods
14.8

 
17.0

Total
$
46.2

 
$
45.2


During the three and six months ended June 30, 2018 we recorded excess and obsolete inventory charges of $3.5 million and $5.5 million, respectively, in cost of goods sold primarily related to the approval and launch of our G6 System and the continuous improvement and innovation of our products.

Property and Equipment
 
June 30, 2018
 
December 31, 2017
Building (1)
$
6.0

 
$
6.0

Furniture and fixtures
8.4

 
5.7

Computer equipment
27.7

 
25.6

Machinery and equipment
61.9

 
33.8

Leasehold improvements
79.1

 
41.7

Construction in progress
39.2

 
87.6

Total
222.3

 
200.4

Accumulated depreciation and amortization
(65.5
)
 
(54.8
)
Property and equipment, net
$
156.8

 
$
145.6

(1) As described in Footnote 6 “Commitments and Contingencies,” although we do not legally own these premises, we were deemed the owner of the construction project during the construction period of our new manufacturing facility in Mesa, Arizona under a build-to-suit lease arrangement.
Accounts Payable and Accrued Liabilities
 
June 30, 2018
 
December 31, 2017
Accounts payable trade
$
59.9

 
$
46.7

Accrued tax, audit, and legal fees
15.4

 
7.1

Accrued rebates
19.9

 
13.9

Accrued warranty
7.5

 
8.8

Accrued other
15.2

 
10.7

Total
$
117.9

 
$
87.2



Accrued Warranty
Warranty costs are reflected in the consolidated statements of operations as product cost of sales. A reconciliation of our accrued warranty costs for the three and six months ended June 30, 2018 and 2017 were as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2018
 
2017
 
2018
 
2017
Beginning balance
$
8.9

 
$
9.9

 
$
8.8

 
$
9.8

Charges to costs and expenses
3.4

 
3.4

 
7.9

 
8.4

Costs incurred
(4.8
)
 
(5.0
)
 
(9.2
)
 
(9.9
)
Ending balance
$
7.5

 
$
8.3

 
$
7.5

 
$
8.3



Other Liabilities
 
June 30, 2018
 
December 31, 2017
Financing lease obligations
$
7.3

 
$
6.7

Deferred rent
8.1

 
8.7

Other
4.2

 
2.8

Total
$
19.6

 
$
18.2

Short Term Marketable Securities, Available for Sale
Short-Term Marketable Securities
Short-term marketable securities, consisting of equity and debt securities, were as follows:
 
June 30, 2018
 
Cost or Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
 
 
 
 
 
 
 
 
Equity investment in Tandem Diabetes Care, Inc
$
5.0

 
$
50.1

 
$

 
$
55.1

 
 
 
 
 
 
 
 
Debt securities, available for sale
 
 
 
 
 
 
 
U.S. government agencies
$
199.6

 
$

 
$
(0.2
)
 
$
199.4

Commercial paper
49.3

 

 

 
49.3

Corporate debt
2.1

 

 

 
2.1

Total available-for-sale debt securities
$
251.0

 
$

 
$
(0.2
)
 
$
250.8

 
 
 
 
 
 
 
 
Total marketable securities
$
256.0

 
$
50.1

 
$
(0.2
)
 
$
305.9

Gross unrealized gain on our equity investment in Tandem Diabetes Care, Inc. of $42.7 million and $50.1 million for three and six months ended June 30, 2018, respectively is included in our Consolidated Statements of Operations under "Income from equity investments."
 
December 31, 2017
 
Amortized
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Market
Value
U.S. government agencies
$
87.5

 
$

 
$
(0.2
)
 
$
87.3

Corporate debt
14.7

 

 

 
14.7

Commercial paper
5.1

 

 

 
5.1

Total marketable securities
$
107.3

 
$

 
$
(0.2
)
 
$
107.1


As of June 30, 2018, the estimated market value of available-for-sale marketable securities with contractual maturities of up to one year and up to 13 months were $249.8 million and $1.0 million, respectively. We do not generally intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.
Inventory
Inventory
 
June 30, 2018
 
December 31, 2017
Raw materials
$
21.7

 
$
20.0

Work-in-process
9.7

 
8.2

Finished goods
14.8

 
17.0

Total
$
46.2

 
$
45.2

Property, Plant and Equipment
Property and Equipment
 
June 30, 2018
 
December 31, 2017
Building (1)
$
6.0

 
$
6.0

Furniture and fixtures
8.4

 
5.7

Computer equipment
27.7

 
25.6

Machinery and equipment
61.9

 
33.8

Leasehold improvements
79.1

 
41.7

Construction in progress
39.2

 
87.6

Total
222.3

 
200.4

Accumulated depreciation and amortization
(65.5
)
 
(54.8
)
Property and equipment, net
$
156.8

 
$
145.6

(1) As described in Footnote 6 “Commitments and Contingencies,” although we do not legally own these premises, we were deemed the owner of the construction project during the construction period of our new manufacturing facility in Mesa, Arizona under a build-to-suit lease arrangement.
Accounts Payable and Accrued Liabilities
Accounts Payable and Accrued Liabilities
 
June 30, 2018
 
December 31, 2017
Accounts payable trade
$
59.9

 
$
46.7

Accrued tax, audit, and legal fees
15.4

 
7.1

Accrued rebates
19.9

 
13.9

Accrued warranty
7.5

 
8.8

Accrued other
15.2

 
10.7

Total
$
117.9

 
$
87.2

Accrued Warranty
Accrued Warranty
Warranty costs are reflected in the consolidated statements of operations as product cost of sales. A reconciliation of our accrued warranty costs for the three and six months ended June 30, 2018 and 2017 were as follows:
 
Three Months Ended 
 June 30,
 
Six Months Ended 
 June 30,
 
2018
 
2017
 
2018
 
2017
Beginning balance
$
8.9

 
$
9.9

 
$
8.8

 
$
9.8

Charges to costs and expenses
3.4

 
3.4

 
7.9

 
8.4

Costs incurred
(4.8
)
 
(5.0
)
 
(9.2
)
 
(9.9
)
Ending balance
$
7.5

 
$
8.3

 
$
7.5

 
$
8.3

Other Liabilities
Other Liabilities
 
June 30, 2018
 
December 31, 2017
Financing lease obligations
$
7.3

 
$
6.7

Deferred rent
8.1

 
8.7

Other
4.2

 
2.8

Total
$
19.6

 
$
18.2